Search

Displaying results 3061 - 3070 of 8697 in total
  1. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension.

  3. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.

  4. Drug

    Oxyphencyclimine

    go.drugbank.com/drugs/DB00383
    Approved

    Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.

    Categories: Drugs for Functional Gastrointestinal Disorders
  5. Drug

    PF-4191834

    go.drugbank.com/drugs/DB11645
    Investigational

    PF-4191834 has been investigated for the basic science of Asthma.

  6. Drug

    Tuberculin purified protein derivative

    go.drugbank.com/drugs/DB11601
    Approved

    Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis.

  7. Drug

    Iloperidone

    go.drugbank.com/drugs/DB04946
    ApprovedInvestigational

    Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. … [A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    PD-168393

    go.drugbank.com/drugs/DB07662
    Experimental

    PD-168393 is an epidermal growth factor receptor inhibitor.

  9. Drug

    Guanidine

    go.drugbank.com/drugs/DB00536
    Approved

    A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism.

  10. Drug

    Atractylodes lancea root oil

    go.drugbank.com/drugs/DB14338
    Approved

    It is not an approved drug.

    Mixtures: O Hui White Extreme Blemish Balm